Chemotherapy targeting human thymidylate synthase messenger RNA

针对人胸苷酸合酶信使 RNA 的化疗

• 批准号: 7727632
• 负责人: Thomas C Hermann
• 金额: $ 32.89万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7727632
• 关键词: Affinity; Antineoplastic Agents; Binding; Biochemical; Biological; Biological Assay; Biological Factors; Breast; Cell Line; Cell Membrane Permeability; Chemicals; Colorectal Cancer; Complex; Crystallization; DNA biosynthesis; Data; Development; Drug Delivery Systems; Elements; Enzymes; Genome; Human; Human Cell Line; Hydroxyl Radical; In Vitro; Indium; Initiator Codon; Lead; Ligand Binding; Ligands; Link; Malignant Neoplasms; Messenger RNA; Modeling; Oligonucleotides; Pharmaceutical Preparations; Process; Production; Proteins; RNA; RNA Binding; RNA library; Regulatory Element; Research; Resistance; Resistance development; Series; Site; Source; Specificity; Structure; Structure-Activity Relationship; Testing; Therapeutic; Therapeutic Uses; Thymidylate Synthase; Thymidylate Synthase Inhibitor; Translations; Up-Regulation; X-Ray Crystallography; anti-cancer therapeutic; base; chemotherapy; design; functional group; improved; in vitro Model; in vivo; inhibitor/antagonist; novel; piperidine; prevent; public health relevance; research study; scaffold; small molecule; three dimensional structure; thymidylate; translation assay

DESCRIPTION (provided by applicant): The proposed research is intended to discover novel anti-cancer agents that inhibit expression of thymidylate synthase (TS), the sole intracellular de novo source of thymidylate for DNA biosynthesis. Specifically, we want to synthesize and identify compounds that selectively bind and stabilize a structured regulatory element in the 5' nontranslated region (NTR) of the TS mRNA which contains the translation start codon sequestered in an RNA hairpin element. By preventing access of the cellular translation machinery to the initiation site, TS mRNA-binding compounds would mimic the action of TS protein which acts as a ligand and repressor of its own mRNA. In preliminary experiments we have validated the TS mRNA as a target for translation inhibition via stabilization of the mRNA secondary structure. In the proposed research we will establish an iterative process aiming at the discovery of lead compounds for the development of novel cancer therapeutics for use in combination with existing anti-cancer drugs that target the enzyme but suffer from resistance development via upregulation of TS expression. The specific aims of this project are to: 1) design and synthesize novel RNA-biased ligands based on two classes of heterocycles privileged for RNA binding; 2) design and validate model oligonucleotides representing the regulatory RNA element in the 5'-NTR of TS mRNA for ligand binding studies; 3) determine the three- dimensional structure of the regulatory RNA element in the TS 5'-NTR by X-ray crystallography; 4) develop RNA affinity and target specificity assays for the TS mRNA and identify small molecule binders among the newly synthesized RNA-biased ligands and known RNA-binding natural products; 5) evaluate TS mRNA binders for specific target recognition in binding and in vitro translation assays; 6) test TS-specific translation inhibitors in human cell lines to determine membrane permeability, interference with TS expression and antiproliferative activity; 7) determine the three-dimensional structure of TS mRNA-ligand complexes by X-ray crystallography; 8) design modified ligands with potentially improved binding affinity by using biological activity data and structural information (structure activity relationships, SAR). PUBLIC HEALTH RELEVANCE: This research is aimed at the discovery of novel anti-cancer therapeutics which will greatly increase the efficacy of existing drugs for the treatment of resistant breast and colorectal cancer.

描述（由申请人提供）：拟定的研究旨在发现抑制胸苷酸合成酶（TS）表达的新型抗癌药物，TS是DNA生物合成中胸苷酸的唯一细胞内从头来源。具体而言，我们希望合成和鉴定选择性结合并稳定TS mRNA的5'非翻译区（NTR）中的结构化调节元件的化合物，所述NTR含有隔离在RNA发夹元件中的翻译起始密码子。通过阻止细胞翻译机制进入起始位点，TS mRNA结合化合物将模拟TS蛋白的作用，TS蛋白充当其自身mRNA的配体和阻遏物。在初步实验中，我们已经验证了TS mRNA作为通过稳定mRNA二级结构的翻译抑制的靶点。在拟议的研究中，我们将建立一个迭代过程，旨在发现用于开发新型癌症治疗剂的先导化合物，用于与现有的抗癌药物联合使用，这些抗癌药物靶向该酶，但通过上调TS表达而产生耐药性。本项目的具体目标是：1）设计和合成基于两类具有RNA结合特权的杂环的新型RNA偏向性配体; 2）设计和验证用于配体结合研究的代表TS mRNA 5 '-NTR中调控RNA元件的模型寡核苷酸; 3）通过X射线晶体学确定TS 5'-NTR中调控RNA元件的三维结构; 4）开发TS mRNA的RNA亲和力和靶特异性测定，并在新合成的RNA偏向配体和已知的RNA结合天然产物中鉴定小分子结合剂; 5）在结合和体外翻译测定中评估TS mRNA结合剂的特异性靶识别; 6）测试人细胞系中的TS特异性翻译抑制剂以确定膜渗透性，干扰TS表达和抗增殖活性; 7）通过X射线晶体学确定TS mRNA-配体复合物的三维结构; 8）通过使用生物活性数据和结构信息（结构活性关系，SAR）设计具有潜在改善的结合亲和力的修饰配体。 公共卫生关系：这项研究旨在发现新的抗癌疗法，这将大大提高现有药物治疗耐药乳腺癌和结直肠癌的疗效。